Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 4/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | PYGM | P11217 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.83 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.80 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.80 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.80 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 3/20 | 0.78 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.78 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.78 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.78 |
| ▸ | PTPRC | P08575 | 2/20 | 0.78 |
| ▸ | PTPRF | P10586 | 2/20 | 0.78 |
| ▸ | F3 | P13726 | 2/20 | 0.78 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.78 |
| ▸ | CES1 | P23141 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maslinic Acid SCHEMBL18420546 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL869930 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL14132395 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL24627035 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL5797458 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL23716504 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL12638707 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL22026389 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL21296155 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM | |
| Maslinic Acid SCHEMBL570425 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2AKR1B10GPBAR1PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401435-A1 | MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS | THE UNIVERSITY OF HONG KONG | 2022-12-22 | — | — | US | disclosed |
| CN-115477611-A | MRGPRX2 antagonists for the treatment of pseudoallergy | 香港大学 | 2022-12-16 | — | — | CN | disclosed |
| US-20060235078-A1 | Insulin secretion potentiator | USE-TECHNO CORPORATION | 2006-10-19 | — | — | US | disclosed |
| EP-1674089-A1 | ACCELERATOR FOR INITIAL INSULIN SECRETION | Use-Techno Corporation (JP) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006064583-A1 | TERPENE, METHOD FOR DETERMINING ITS BLOOD CONCENTRATION, AND METHOD FOR ANALYZING ITS PHARMACOKINETICS | USE-TECHNO CORPORATION (JP) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006054370-A1 | GLUCONEOGENESIS INHIBITING AGENT | USE-TECHNO CORPORATION (JP) | 2006-05-26 | — | — | WO | disclosed |
| US-20050143464-A1 | With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts | USE-TECHNO CORPORATION | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143464-A1 | With low side effects, which rapidly stimulate early insulin secretion and suppress blood glucose increase only at mealtimes; antidiabetic agent; triterpene acids or alcohols with picene ring; corosolic acids; oleanene acids; ursenoic acids; banaba plant extracts | GPR119, IRS1, AMY1A | PTPN1 1873/4885PTPN2 2179/4885AKR1B10 1998/4885 |
| US-20060235078-A1 | Insulin secretion potentiator | IAPP, GPR119, IRS1 | PTPN1 1481/4885PTPN2 1100/4885AKR1B10 1544/4885 |
| US-20220401435-A1 | MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS | MRGPRX2, MRGPRX1, MRGPRX4 | PTPN1 2917/4885PTPN2 2221/4885AKR1B10 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.